Ссылки
*Набор реагентов для амплификации и детекции cobas HPV (cobas 4800 HPV Amplification/Detection Kit), РУ ФСЗ 2011/09492
** Система модульная cobas 4800 для ПЦР-диагностики in vitro, РУ ФСЗ 2011/09271
**Жидкость консервирующая SurePath Preservative Fluid, РУ № ФСЗ 2010/06235
**Жидкость PreservCyt Solution для консервирования клеточных образцов РУ № РЗН 2017/6322
**Среда ПЦР для сбора цервикальных мазков cobas PCR Cell Collection Media, РУ № ФСЗ 2011/09492
1. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
2. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer — burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
3. cobas® 4800 HPV Test [инструкция-вкладыш, CE]. Branchburg, NJ: Roche Molecular Systems, Inc; 2012.
4. Heideman DA, Hesselink AT, Berkhof J, et al. Clinical validation of the cobas® 4800 HPV Test for cervical screening purposes. J Clin Microbiol. 2011;49(11):3983-3985. doi: 10.1128/JCM.05552-11.
5. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516-20. doi: 10.1002/ijc.24010.
6. Saville et al. (2018). “Clinical validation of the cobas HPV test on the cobas 6800 system for the purpose of cervical screening” J. Clin. Microbiol. doi:10.1128/JCM.01239-18.